drugset / Trial / NCT05918211
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Timeline
- Start
- 2023-10-30
- Primary completion
- 2025-10-28
- Completion
- 2025-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Udenafil | Small molecule | — | Oral |